COVID-19 convalescent plasma clears SARS-CoV-2 refractory to remdesivir in an infant with congenital heart disease

Blood Adv. 2020 Sep 22;4(18):4278-4281. doi: 10.1182/bloodadvances.2020002507.

Zahidee Rodriguez¹, Andi L Shane², Hans Verkerke³, Christopher Lough⁴, Matthew G Zimmerman^{2

5

6}, Mehul Suthar^{2

5

6}, Jens Wrammert^{2

5}, Heather MacDonald⁷, Michael Wolf¹, Shanelle Clarke¹, John D Roback³, Connie M Arthur³, Sean R Stowell³, Cassandra D Josephson^{3

8}

¹ Division of Cardiology.
² Division of Infectious Disease, Department of Pediatrics, Children's Healthcare of Atlanta, and.
³ Department of Pathology and Laboratory Medicine, Center for Transfusion and Cellular Therapies, Emory University School of Medicine, Atlanta, GA.
⁴ LifeSouth Community Blood Centers, Inc., Gainesville, FL.
⁵ Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA.
⁶ Yerkes National Primate Research Center, Atlanta, GA.
⁷ Department of Pathology, Children's Healthcare of Atlanta, Atlanta, GA; and.
⁸ Department of Pediatrics, Aflac Cancer Center and Blood Disorders Service, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA.

Abstract

COVID-19 convalescent plasma (CP) may be a safe and effective treatment option in SARS-CoV-2 infection refractory to remdesivir.
Infants may benefit from CP despite developing immune systems and donor variability emphasizes the need for characterization prior to use.